FibroBiologics Inc. (NASDAQ:FBLG) Given Consensus Recommendation of “Reduce” by Analysts

Shares of FibroBiologics Inc. (NASDAQ:FBLG) have been assigned an average rating of “Reduce” from the five brokerages that are covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and one has given a buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $73.00.

Several equities research analysts have commented on the company. Wall Street Zen upgraded FibroBiologics from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 13th. HC Wainwright reiterated a “buy” rating and issued a $6.00 target price (down from $8.00) on shares of FibroBiologics in a research note on Tuesday, August 4th. Weiss Ratings downgraded shares of FibroBiologics from a “sell (e+)” rating to a “sell (e)” rating in a report on Thursday, August 20th. Finally, Deutsche Bank Aktiengesellschaft cut shares of FibroBiologics to an “underperform” rating in a report on Tuesday, August 4th.

FibroBiologics Stock Down 7.6%

Shares of FBLG stock opened at $1.95 on Friday. The stock has a market cap of $12.98 million, a PE ratio of -0.38 and a beta of 1.61. The business has a 50-day simple moving average of $1.01 and a 200-day simple moving average of $2.17. FibroBiologics has a 52-week low of $0.62 and a 52-week high of $12.43.

FibroBiologics (NASDAQ:FBLG) last posted its earnings results on Friday, July 31st. The company reported ($0.66) EPS for the quarter, topping the consensus estimate of ($0.93) by $0.27. Sell-side analysts anticipate that FibroBiologics will post -3 earnings per share for the current fiscal year.

Hedge Funds Weigh In On FibroBiologics

Several institutional investors and hedge funds have recently modified their holdings of FBLG. Landscape Capital Management L.L.C. purchased a new position in FibroBiologics during the third quarter worth approximately $191,000. Geode Capital Management LLC increased its position in shares of FibroBiologics by 20.7% in the fourth quarter. Geode Capital Management LLC now owns 348,761 shares of the company’s stock valued at $78,000 after buying an additional 59,813 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of FibroBiologics by 287.3% in the fourth quarter. Renaissance Technologies LLC now owns 231,600 shares of the company’s stock valued at $52,000 after buying an additional 171,800 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of FibroBiologics during the 4th quarter worth approximately $34,000. Finally, Cerity Partners LLC raised its stake in shares of FibroBiologics by 37.2% during the 2nd quarter. Cerity Partners LLC now owns 128,109 shares of the company’s stock worth $80,000 after buying an additional 34,702 shares during the period.

About FibroBiologics

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc was incorporated in 2021 and is based in Houston, Texas.